)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Keenova Therapeutics
Keenova Therapeutics (MNK) investor relations material
Keenova Therapeutics has been private
Keenova Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary10 Nov, 2026
Executive summary
Q3 continuing-operations net sales were $549.5M, up 32.1% YoY; comparison was affected by Endo acquisition timing and a full quarter of XIAFLEX sales.
Strong core-brand performance and merger synergies supported higher FY 2026 net sales and Adjusted EBITDA guidance.
Financial highlights
Pro forma continuing-operations net sales were $544.1M versus $464.4M in Q3'25; Q3 reported sales were $549.5M.
Q3 Adjusted EBITDA from continuing operations was $232.5M; loss from continuing operations narrowed to $96.1M from $242.0M.
Nine-month continuing-operations net loss widened to $430.1M from $347.7M, reflecting impairment and divestiture losses.
Q3 gross profit was $335.1M versus $172.4M; continuing-operations cash from operations for 9M was $290.0M versus $41.1M used in the prior-year period.
Outlook and guidance
FY 2026 net sales guidance, excluding Percocet, increased to $2.00B–$2.025B; Adjusted EBITDA guidance rose to $750M–$770M.
Acthar Gel growth guidance remained 20%–22%; XIAFLEX growth guidance increased to 10%–11%.
Guidance includes anticipated 2026 merger synergies and excludes future M&A or divestitures.
Plantar fibromatosis sBLA submission is targeted for Q1 2027; Phase III hammer toe study enrollment began in August 2026.
Q4 comparisons face Acthar Gel shipping-day headwinds and reversal of XIAFLEX’s Q3 shipment-timing benefit.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Keenova Therapeutics
- Q2 2026 net sales jumped 96% to $517M, but a $208M impairment drove a $221M loss.MNK
Q2 2026 - Q1 2026 net sales doubled, but merger costs led to a $113.5M–$114M operating loss.MNKQ1 2026
- 2026 AGM features key votes on directors, auditors, compensation, capital, and U.S. listing readiness.MNKProxy filing
- AGM to vote on directors, auditor, executive pay, capital reduction, and U.S. listing readiness.MNKProxy filing
- Double-digit growth in 2025, strong cash flow, and robust 2026 outlook driven by core franchises.MNKQ4 2025
- Q3 2025 net sales up 49% to $753.1M, led by Acthar Gel growth and Endo merger contributions.MNKQ3 2025
- Merger completed, branded growth drives 2025 outlook with sales guided up to $3.62B.MNKQ2 2025
- Q2 sales up 8.3%, guidance raised, and Therakos sale to reduce net debt by 50%+.MNKQ2 2024
- Net sales rose, losses narrowed, and Therakos sale will cut net debt by over 60%.MNKQ3 2024
Keenova Therapeutics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Mallinckrodt plc is a specialty pharmaceutical company that focuses on developing, manufacturing, and commercializing treatments for autoimmune and rare diseases, as well as therapies for pain management and critical care. The company’s portfolio includes a range of branded and generic pharmaceuticals, with a strong emphasis on specialty therapies for conditions such as neurology, nephrology, rheumatology, and pulmonology. Mallinckrodt also offers imaging agents used in diagnostic procedures. Its products are primarily distributed to hospitals, physicians, and healthcare providers. The company is headquartered in Dublin, Ireland, and its shares are listed on the New York Stock Exchange.